These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 11502877)
1. Inhibition of thymidylate synthase activity by antisense oligodeoxynucleotide and possible role in thymineless treatment. Lin SB; Ts'o PO; Sun SK; Choo KB; Yang FY; Lim YP; Tsai HL; Au LC Mol Pharmacol; 2001 Sep; 60(3):474-9. PubMed ID: 11502877 [TBL] [Abstract][Full Text] [Related]
2. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Grem JL; Danenberg KD; Behan K; Parr A; Young L; Danenberg PV; Nguyen D; Drake J; Monks A; Allegra CJ Clin Cancer Res; 2001 Apr; 7(4):999-1009. PubMed ID: 11309351 [TBL] [Abstract][Full Text] [Related]
3. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase. Berg RW; Werner M; Ferguson PJ; Postenka C; Vincent M; Koropatnick DJ; Behrend E J Pharmacol Exp Ther; 2001 Aug; 298(2):477-84. PubMed ID: 11454908 [TBL] [Abstract][Full Text] [Related]
4. Desensitization and sensitization of cells to fluoropyrimidines with different antisenses directed against thymidylate synthase messenger RNA. Ju J; Kane SE; Lenz HJ; Danenberg KD; Chu E; Danenberg PV Clin Cancer Res; 1998 Sep; 4(9):2229-36. PubMed ID: 9748143 [TBL] [Abstract][Full Text] [Related]
5. Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Ferguson PJ; Collins O; Dean NM; DeMoor J; Li CS; Vincent MD; Koropatnick J Br J Pharmacol; 1999 Aug; 127(8):1777-86. PubMed ID: 10482907 [TBL] [Abstract][Full Text] [Related]
6. A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance. Berg RW; Ferguson PJ; Vincent MD; Koropatnick DJ Cancer Gene Ther; 2003 Apr; 10(4):278-86. PubMed ID: 12679800 [TBL] [Abstract][Full Text] [Related]
7. Antisense thymidylate synthase electrogene transfer to increase uptake of radiolabeled iododeoxyuridine in a murine model. Chi KH; Wang HE; Wang YS; Chou SL; Yu HM; Tseng YH; Hwang IM; Lui WY J Nucl Med; 2004 Mar; 45(3):478-84. PubMed ID: 15001691 [TBL] [Abstract][Full Text] [Related]
8. Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed. Di Cresce C; Figueredo R; Ferguson PJ; Vincent MD; Koropatnick J J Pharmacol Exp Ther; 2011 Sep; 338(3):952-63. PubMed ID: 21673071 [TBL] [Abstract][Full Text] [Related]
9. Enhancement of 5-fluoro-2'-deoxyuridine antineoplastic activity by 5-benzyloxybenzyloxybenzylacyclouridine in a human colon carcinoma cell line. Chu E; Chu MY; Darnowski JW; Chen ZH; Pan BC; Chu SH Cancer Res; 1992 Apr; 52(7):1729-36. PubMed ID: 1532344 [TBL] [Abstract][Full Text] [Related]
10. Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells. Ferguson PJ; DeMoor JM; Vincent MD; Koropatnick J Br J Pharmacol; 2001 Dec; 134(7):1437-46. PubMed ID: 11724749 [TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Berger SH; Jenh CH; Johnson LF; Berger FG Mol Pharmacol; 1985 Nov; 28(5):461-7. PubMed ID: 2932632 [TBL] [Abstract][Full Text] [Related]
12. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil. Matsuoka K; Tsukuda K; Suda M; Kobayashi K; Ota T; Okita A; Watanabe K; Suzuki E; Murakami M; Doihara H; Shimizu N Int J Oncol; 2004 Jan; 24(1):217-22. PubMed ID: 14654960 [TBL] [Abstract][Full Text] [Related]
13. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition. Sakoff JA; Howitt IJ; Ackland SP; McCluskey A Cancer Chemother Pharmacol; 2004 Mar; 53(3):225-32. PubMed ID: 14648018 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model. van Laar JA; van der Wilt CL; Rustum YM; Noordhuis P; Smid K; Pinedo HM; Peters GJ Clin Cancer Res; 1996 Aug; 2(8):1327-33. PubMed ID: 9816304 [TBL] [Abstract][Full Text] [Related]
15. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858 [TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase as a determinant of 5-fluoro-2'-deoxyuridine response in human colonic tumor cell lines. Berger SH; Berger FG Mol Pharmacol; 1988 Oct; 34(4):474-9. PubMed ID: 2971871 [TBL] [Abstract][Full Text] [Related]
18. A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'-deoxyuridine in a human colon tumor cell line. Berger SH; Barbour KW; Berger FG Mol Pharmacol; 1988 Oct; 34(4):480-4. PubMed ID: 2971872 [TBL] [Abstract][Full Text] [Related]
19. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents. Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040 [TBL] [Abstract][Full Text] [Related]
20. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Welsh SJ; Titley J; Brunton L; Valenti M; Monaghan P; Jackman AL; Aherne GW Clin Cancer Res; 2000 Jun; 6(6):2538-46. PubMed ID: 10873110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]